391 related articles for article (PubMed ID: 31101091)
21. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
22. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
[TBL] [Abstract][Full Text] [Related]
23. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).
Miura M; Kobayashi T; Igarashi T; Hamada H; Iwata N; Sasaki Y; Matsukawa M; Sato N; Kubo H; Takei S
Pediatr Infect Dis J; 2020 Jan; 39(1):41-47. PubMed ID: 31815838
[TBL] [Abstract][Full Text] [Related]
24. Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort.
Fabi M; Andreozzi L; Corinaldesi E; Bodnar T; Lami F; Cicero C; Tchana B; Landini C; Sprocati M; Bigucci B; Balsamo C; Sogno Valin P; Di Fazzio G; Iughetti L; Valletta E; Marchetti F; Donti A; Lanari M
Eur J Pediatr; 2019 Mar; 178(3):315-322. PubMed ID: 30499051
[TBL] [Abstract][Full Text] [Related]
25. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.
Xue LJ; Wu R; Du GL; Xu Y; Yuan KY; Feng ZC; Pan YL; Hu GY
Clin Rev Allergy Immunol; 2017 Jun; 52(3):389-400. PubMed ID: 27550227
[TBL] [Abstract][Full Text] [Related]
26. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Cavaletti G; Giannini F; Sabatelli M; Beghi E;
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):729-34. PubMed ID: 25246645
[TBL] [Abstract][Full Text] [Related]
27. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
Sundel RP; Baker AL; Fulton DR; Newburger JW
J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187
[TBL] [Abstract][Full Text] [Related]
28. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
29. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
Li X; Chen Y; Tang Y; Ding Y; Xu Q; Sun L; Qian W; Qian G; Qin L; Lv H
Eur J Pediatr; 2018 Aug; 177(8):1279-1292. PubMed ID: 29948255
[TBL] [Abstract][Full Text] [Related]
30. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
31. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T; Wang Y; Fu S; Wang W; Xie C; Zhang Y; Gong F
Pediatr Rheumatol Online J; 2017 Mar; 15(1):17. PubMed ID: 28320400
[TBL] [Abstract][Full Text] [Related]
32. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
33. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
Saji T; Takatsuki S; Kobayashi T
Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
[TBL] [Abstract][Full Text] [Related]
34. Methylprednisolone pulse therapy for massive lymphadenopathy in a child with intravenous immunoglobulin-resistant Kawasaki disease.
Chen HH; Liu PM; Bong CN; Wu YT; Yang KD; Wang CL
J Microbiol Immunol Infect; 2005 Apr; 38(2):149-52. PubMed ID: 15843862
[TBL] [Abstract][Full Text] [Related]
35. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone.
Ogata S; Ogihara Y; Nomoto K; Akiyama K; Nakahata Y; Sato K; Minoura K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2009 Nov; 66(5):577-84. PubMed ID: 19680167
[TBL] [Abstract][Full Text] [Related]
36. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
Zheng X; Li J; Yue P; Liu L; Li J; Zhou K; Hua Y; Li Y
PLoS One; 2021; 16(3):e0248812. PubMed ID: 33764989
[TBL] [Abstract][Full Text] [Related]
37. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
[TBL] [Abstract][Full Text] [Related]
38. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive therapies in Kawasaki disease.
Tremoulet AH
Int J Rheum Dis; 2018 Jan; 21(1):76-79. PubMed ID: 29076637
[TBL] [Abstract][Full Text] [Related]
40. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
